Search alternatives:
patients decrease » point decrease (Expand Search), treatments decreased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
patients decrease » point decrease (Expand Search), treatments decreased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.
Published 2025“…<p>Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.</p>…”
-
7
-
8
-
9
Apoptosis inhibitor prevented the decrease of IIL ESP-induced TJs expression and alleviated barrier disruption of Caco-2 monolayer.
Published 2025“…<p><b>A:</b> Apoptosis inhibitor Z-VAD-FMK pretreatment increased the IIL ESP-decreased TEER. …”
-
10
-
11
-
12
-
13
-
14
-
15
-
16
Flow chart of included patients and dropouts.
Published 2025“…</p><p>Conclusions</p><p>The patients walked with reduced hip flexion, heel strike angle and toe-off angle, and had shorter strides, decreased velocity, and increased time for swing and single support, compared to HI. …”
-
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
18
-
19
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
20
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: